NCT05046873View on ClinicalTrials.gov

A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 6, 2021

Primary Completion Date

January 5, 2022

Study Completion Date

January 5, 2022

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL

Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.

DRUG

semaglutide 1.34 mg/mL (placebo)

Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.

DRUG

Semaglutide 1.34 mg/mL

The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.

DRUG

NNC0480-0389 A 10 mg/mL

The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.

Trial Locations (1)

14050

Novo Nordisk Investigational Site, Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY